Lanean...
Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity
Recently reported cardiovascular outcome studies on empagliflozin (EMPA-REG) and liraglutide (LEADER) have spurred interest in this field of diabetology. This commentary compares and contrasts these studies with two equally important outcome trials conducted using blood pressure lowering agents. A c...
Gorde:
| Argitaratua izan da: | Indian J Endocrinol Metab |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Medknow Publications & Media Pvt Ltd
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5240071/ https://ncbi.nlm.nih.gov/pubmed/28217527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.194341 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|